Medical device firm completes takeover of antibiotic bone cement manufacturer
International medical device firm Biocomposites has acquired the remaining shares of an antibiotic bone cement manufacturer and distributor.
Biocomposites made a majority investment in the SYNICEMTM and Subiton products in 2022, developed by Laboratorios SL S.A. and Synergie Ingénierie Médicale S.A.R.L. Products provide surgeons with reliable tools for infection treatment in challenging environments.
Keele-based Biocomposites engineers, manufactures and markets products for use in infection management in bone and soft tissue. Its products regenerate bone and target infection risks across a variety of specialities, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry, and sports injuries. Biocomposites products are now used in more than one million procedures per annum and sold in more than 100 countries around the world.
It has global operations across Europe, the US, Argentina, Canada, China, and India developing innovative calcium compounds and bone cements for surgical use.
Squire Patton Boggs advised Biocomposites on both acquisitions. The team advising Biocomposites on the latest transaction was led by Corporate partner David Milne and senior associate Joshua Astill-Headley.
Simon G. Greenhalgh, Group Chief Financial Officer at Biocomposites, said: “This was an important acquisition for our company, building on the success of our initial investment in the SYNICEM and Subiton products and our strategic aim to drive further product innovation in bone and soft tissue infections.
“Squire Patton Boggs provided expert advice to us at every stage of this journey, with first-class support from David, Josh and the team. Their in-depth knowledge of our business, coupled with a practical and very commercial approach to getting the deal done, was impressive – particularly since we were working under the pressure of a challenging timescale. We are grateful of their efforts and continued support.”
